Potential role of statins in the treatment of heart failure

Current Atherosclerosis Reports

Volumn 10, Issue 4, 2008, Pages 318-323

  Katz, Stuart D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; DOCOSAHEXAENOIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; LOW DRUG DOSE; MORTALITY; MUSCLE DISEASE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; STROKE;

FLUOROBENZENES; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIMIDINES; SULFONAMIDES;

EID: 58549093995     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0049-4     Document Type: Article

References (35)

1. Adams KF Jr, Zannad F: Clinical definition and epidemiology of advanced heart failure. Am Heart J 1998, 135: S204-S215.
2. Raina A, Pickering T, SAimbo D: Statin use in heart failure: a cause for concern? Am Heart J 2006, 152: 39-49.
3. Khush KK, Waters DD: Effects of statin therapy on the development and progression of heart failure: Mechanisms and clinical trials. J Card Fail 2006, 12: 664-674.
4. Martin JH, Krum H: Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007, 113: 119-127.
5. van der Harst P, Voors AA, van Gilst WH, et al.: Statins in the treatment of chronic heart failure: A systematic review. PLoS Med 2006, 3: E333.
6. Ramasubbu K, Estep J, White DL, et al.: Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 2008, 51: 415-426.
7. Liao JK: Statin therapy for cardiac hypertrophy and heart failure. J Investig Med 2004, 52: 248-253.
8. Packer M: Pathophysiology of chronic heart failure. Lancet 1992, 340: 88-92.
9. Katz SD: The role of endothelium-derived vasoactive substances in the pathophysiology of exercise intolerance in patients with congestive heart failure. Prog Cardiovasc Dis 1995, 38: 23-50.
10. Katz AM: Aeart failure: a hemodynamic disorder complicated by maladaptive proliferative responses. J Cell Mol Med. 2003, 7: 1-10.
11. Cohn JN: Global structural ventriculSr remodeling: summation. J Card Fail 2002, 8: S269-S270.
12. Katz SD, Hryniewicz K, Hriljac I, et al.: Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure. Circulation 2005, 111: 310-314.
13. Horwich TB, MacLellan WR, Fonarow GC: Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004, 43: 642-648.
14. Mozaffarian D, Nye R, Levy WC: Statin therapy is associated with lower mortality among patients with severe heart failure. Am J Cardiol 2004, 93: 1124-1129.
15. Anker SD, Clark AL, Winkler R, et al.: Statin use and survival in patients with chronic heart failure - results from two observational studies with 5200 patients. Int J Cardiol 2006, 112: 234-242.
16. Foody JM, Shah R, Galusha D, et al.: Statins and mortality among elderly patients hospitalized with heart failure. Circulation 2006, 113: 1086-1092.
17. Go AS, Lee WY, Yang J, et al.: Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006, 296: 2105-2111.
18. Ray JG, Gong Y, Sykora K, Tu JV: Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005, 165: 62-67.
19. Dickinson MG, Ip JH, Olshansky B, et al.: Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: Mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007, 153: 573-578.
20. Krum H, Bailey M, Meyer W, et al.: Impact of statin therapy on clinical outcomes in chronic heart failure patients according to beta-blocker use: Results of CIBIS II. Cardiology 2007, 108: 28-34.
21. Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108: 839-843.
22. Tousoulis D, Antoniades C, Bosinakou E, et al.: Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005, 178: 359-363.
23. Sola S, Mir MQ, Lerakis S, et al.: Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006, 47: 332-337.
24. Strey CH, Young JM, Lainchbury JH, et al.: Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart 2006, 92: 1603-1609.
25. Wojnicz R, Wilczek K, Nowalany-Kozielska E, et al.: Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol 2006, 97: 899-904.
26. Krum H, Ashton E, Reid C, et al.: Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure. J Card Fail 2007, 13: 1-7.
27. Bleske BE, Nicklas JM, Bard RL, et al.: Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level. J Am Coll Cardiol 2006, 47: 338-341.
28. Sacks FM, Pfeffer MA, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996, 335: 1001-1009.
29. Kjekshus J, Apetrei E, Barrios V, et al.: Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007, 357: 2248-2261.
30. Tavazzi L, Tognoni G, Franzosi MG, et al.: Rationale and design of the GISSI heart failure trial: A large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failure. Eur J Heart Fail 2004, 6: 635-641.
31. Sharpe N: Clinical trials and She real world: selection bias and generalisability of trial results. Cardiovasc Drugs Ther 2002, 16: 75-77.
32. Skali H, Pfeffer MA, Lubsen J, Solomon SD: Variable impact of combining fatal and nonfatal end points in heart failure trials. Circulation 2006, 114: 2298-2303.
33. Chiang CL: Competing risks in mortality analysis. Annu Rev Public Health 1991, 12: 281-307.
34. Tesar BM, Walker WE, Unternaehrer J, et al.: Murine [corrected] myeloid dendritic cell-dependent toll-like receptor immunity is preserved with aging. Aging Cell 2006, 5: 473-486.
35. Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000, 342: 1887-1892